1 Small-Cap Stock With 10X Potential
"The early bird gets the worm." We can apply this familiar saying to investing in stocks. Getting in on a promising company before its shares skyrocket can translate into market-shattering returns in the long run. Of course, many companies haven't garnered much attention yet simply because they are high-risk investments.
It's essential to keep this fact in mind when looking for potential under-the-radar gems. With that said, let's look at a promising biotech that could perform very well in the next six months and beyond: NRx Pharmaceuticals (NASDAQ: NRXP). This company has a market cap of only $535 million -- but if its master plan actualizes, its shares could go through the roof.
NRx Pharmaceuticals is a clinical-stage biotech, but it does have a promising pipeline program. The product in question is called Aviptadil, and it is a potential treatment for COVID-19. Aviptadil is primarily aimed at severe coronavirus patients with respiratory failure. In a phase 2b/3 clinical trial, the 60-day survival rate of critically ill COVID-19 patients treated with Aviptadil was 81%, compared to just 21% for those on the current standards of care.
Source Fool.com